Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Chugai to Offload 13 Off-Patent Brands to Taiyo Holdings
Chugai Pharmaceutical said on November 14 that it and its Swiss parent Roche are transferring the Japanese marketing authorization for 13 off-patent brands to a new pharma subsidiary set up under solder resist maker Taiyo Holdings. The step-by-step transfer of…
To read the full story
Related Article
- Chugai Completes Transfer of 13 Off-Patent Brands to Taiyo
January 10, 2019
- Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO
January 10, 2018
- Chugai Executes Asset Transfer for 13 Off-Patent Brands
January 9, 2018
- Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
November 16, 2017
- Reported Off-Patent Drug Divestment “Not Based on Announcement”: Chugai
November 14, 2017
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…